Molecular Docking of 3-Methylindole-containing Drugs Binding into CYP3A4

Abstract

Abstract: Drugs SPD-304(6,7-dimethyl-3-{[methyl-(2-{methyl-[1-(3-trifluoromethyl-phenyl)-1H-indol-3-ylmethyl]- amino}-ethyl)-amino]-methyl}-chromen-4-one) and zafirlukast contain a common structural element of 3-substituted indole moiety which closely relates to a dehydrogenated reaction catalyzed by cytochrome P450s(CYPs). It was reported that the dehydrogenation can produce a reactive electrophilic intermediate which cause toxicities and inactivate CYPs. Drug L-745,870(3-{[4-(4-chlorophenyl)piperazin-1-yl]-methyl}-1H-pyrrolo- 2,3-β-pyridine) might have similar effect since it contains the same structural element. We used molecular docking approach combined with molecular dynamics(MD) simulation to model three-dimensional(3D) complex structures of SPD-304, zafirlukast and L-745,870 into CYP3A4, respectively. The results show that these three drugs can stably bind into the active site and the 3-methylene carbons of the drugs keep a reasonable reactive distance from the heme iron. The complex structure of SPD-304-CYP3A4 is in agreement with experimental data. For zafirlukast, the calculation results indicate that 3-methylene carbon might be the dehydrogenation reaction site. Docking model of L-745,870-CYP3A4 shows a potential possibility of L-745,870 dehydrogenated by CYP3A4 at 3-methylene carbon which is in agreement with experiment in vivo. In addition, residues in the phenylalanine cluster as well as S119 and R212 play a critical role in the ligands binding based on our calculations. The docking models could provide some clues to understand the metabolic mechanism of the drugs by CYP3A4.

Key words: CYP3A4, Molecular docking, Molecular dynamics(MD) simulation

MENG Xuan-yu, LI Zhuo, NIU Rui-juan, ZHANG Hong-xing, ZHENG Qing-chuan. Molecular Docking of 3-Methylindole-containing Drugs Binding into CYP3A4[J]. Chemical Research in Chinese Universities, 2012, 28(1): 137-141.

References

[1] de Graaf C., Vermeulen N. P., Feenstra K. A., J. Med. Chem., 2005,48, 2725 [2] Denisov I. G., Makris, T. M., Sligar S. G., Schlichting I., Chem. Rev.,2005, 105, 2253 [3] Dresser G. K., Spence, J. D., Bailey D. G., Clin. Pharmacokinet,2000, 38, 41 [4] He M. M., Smith A. S., Oslob J. D., Flanagan W. M., Braisted A. C.,Whitty A., Cancilla M. T., Wang J., Lugovskoy A. A., Yoburn J. C.,Fung A. D., Farrington G., Eldredge J. K., Day E. S., Cruz L. A.,Cachero T. G., Miller S. K., Friedman J. E., Choong I. C., CunninghamB. C., Science, 2005, 310, 1022 [5] Danese S., De Vitis I., Gasbarrini A., Ann. Intern. Med., 2001, 135,930 [6] Patel S., Freedman S., Chapman K. L., Emms F., Fletcher A. E.,Knowles M., Marwood R., McAllister G., Myers J., Curtis N., KulagowskiJ. J., Leeson P. D., Ridgill M., Graham M., Matheson S.,Rathbone D., Watt A. P., Bristow L. J., Rupniak N. M., Baskin E.,Lynch J. J., Ragan C. I., J. Pharmacol. Exp. Ther., 1997, 283, 636 [7] Tanaka K., Okada Y., Kanno T., Otomo A., Yanagisawa Y., Shouguchi-Miyata J., Suga E., Kohiki E., Onoe K., Osuga H., Aoki M., HadanoS., Itoyama Y., Ikeda J. E., Exp. Neurol., 2008, 211, 378 [8] Sun H., Yost G. S., Chem. Res. Toxicol., 2008, 21, 374 [9] Kassahun K., Skordos K., McIntosh I., Slaughter D., Doss G. A.,Baillie T. A., Yost G. S., Chem. Res. Toxicol., 2005, 18, 1427 [10] Zhang K. E., Kari P. H., Davis M. R., Doss G., Baillie T. A., Vyas K.P., Drug. Metab. Dispos., 2000, 28, 633 [11] Jorgensen W. L., Science, 2004, 303, 1813 [12] Zhang J. L., Guo Y. H., Gao C. H., Wang E. S., Ren Z. Y., Fang X. X.,Wang J. D., Chem. Res. Chinese Universities, 2010, 26(2), 256 [13] Wishart D. S., Knox C., Guo A. C., Shrivastava S., Hassanali M.,Stothard P., Chang Z., Woolsey J., Nucleic Acids Research, 2006, 34,D668 [14] Affinity In Accelrys Inc., Accelrys Inc., San Diego, 1999 [15] Brooks B. R., Bruccoleri R. E., Olafson B. D., States D. J., SwaminathanS., Karplus M., Journal of Computational Chemistry, 1983, 4,187 [16] Williams P. A., Cosme J., Vinkovic D. M., Ward A., Angove H. C.,Day P. J., Vonrhein C., Tickle I. J., Jhoti H., Science, 2004, 305, 683 [17] Yano J. K., Wester M. R., Schoch G. A., Griffin K. J., Stout C. D.,Johnson E. F., J. Biol. Chem., 2004, 279, 38091 [18] Ekroos M., Sjogren T., Proc. Natl. Acad. Sci. USA, 2006, 103, 13682 [19] Sevrioukova I. F., Poulos T. L., Proc. Natl. Acad. Sci. USA, 2010,107, 18422 [20] Guengerich F. P., Hosea N. A., Parikh A., Bell-Parikh L. C., JohnsonW. W., Gillam E. M., Shimada T., Drug Metab. Dispos., 1998, 26,1175 [21] Payne V. A., Chang Y. T., Loew G. H., Proteins-Structure Functionand Genetics, 1999, 37, 204 [22] Li W. H., Tang Y., Liu H., Cheng J. G., Zhu W. L., Jiang H. L., Proteins-Structure Function and Bioinformatics, 2008, 71, 938 [23] Morris G. M., Goodsell D. S., Halliday R. S., Huey R., Hart W. E.,Belew R. K., Olson A. J., Journal of Computational Chemistry, 1998,19, 1639 [24] Poulos T. L., Finzel B. C., Howard A. J., J. Mol. Biol., 1987, 195,687 [25] Kartha J. S., Yost G. S., Drug Metab. Dispos., 2008, 36, 155